These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 2702642

  • 21. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
    Wang JJ, Teng CS.
    Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
    [Abstract] [Full Text] [Related]

  • 22. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT.
    Mol Cell Endocrinol; 2003 Dec 15; 211(1-2):37-42. PubMed ID: 14656474
    [Abstract] [Full Text] [Related]

  • 23. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.
    Ueno S, Manganaro TF, Donahoe PK.
    Endocrinology; 1988 Sep 15; 123(3):1652-9. PubMed ID: 2456917
    [Abstract] [Full Text] [Related]

  • 24. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
    Fuller AF, Guy S, Budzik GP, Donahoe PK.
    J Clin Endocrinol Metab; 1982 May 15; 54(5):1051-5. PubMed ID: 6895900
    [Abstract] [Full Text] [Related]

  • 25. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat.
    Tsuji M, Shima H, Yonemura CY, Brody J, Donahoe PK, Cunha GR.
    Endocrinology; 1992 Sep 15; 131(3):1481-8. PubMed ID: 1505479
    [Abstract] [Full Text] [Related]

  • 26. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
    Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA.
    Gynecol Oncol; 2008 Jan 15; 108(1):141-8. PubMed ID: 17988723
    [Abstract] [Full Text] [Related]

  • 27. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK.
    Development; 2006 Jun 15; 133(12):2359-69. PubMed ID: 16687449
    [Abstract] [Full Text] [Related]

  • 28. Mullerian-inhibiting substance secretion is delayed in XX sex-reversed dog embryos.
    Meyers-Wallen VN, MacLaughlin D, Palmer V, Donahoe PK.
    Mol Reprod Dev; 1994 Sep 15; 39(1):1-7. PubMed ID: 7999353
    [Abstract] [Full Text] [Related]

  • 29. Molecular biology of MIS and its receptors.
    Teixeira J, Donahoe PK.
    J Androl; 1996 Sep 15; 17(4):336-41. PubMed ID: 8889695
    [Abstract] [Full Text] [Related]

  • 30. Paracrine-mediated apoptosis in reproductive tract development.
    Roberts LM, Hirokawa Y, Nachtigal MW, Ingraham HA.
    Dev Biol; 1999 Apr 01; 208(1):110-22. PubMed ID: 10075845
    [Abstract] [Full Text] [Related]

  • 31. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.
    Seifer DB, Maclaughlin DT.
    Fertil Steril; 2007 Sep 01; 88(3):539-46. PubMed ID: 17559842
    [Abstract] [Full Text] [Related]

  • 32. Developmental expression and cellular distribution of Mullerian inhibiting substance in the primate ovary.
    Modi D, Bhartiya D, Puri C.
    Reproduction; 2006 Sep 01; 132(3):443-53. PubMed ID: 16940285
    [Abstract] [Full Text] [Related]

  • 33. Human recombinant mullerian inhibiting substance inhibits epidermal growth factor.
    Coughlin JP, Cigarroa F, Donahoe PK, McLaughlin DT.
    Curr Surg; 1988 Sep 01; 45(3):204-5. PubMed ID: 3402255
    [No Abstract] [Full Text] [Related]

  • 34. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
    Yin X, Ouyang S, Xu W, Zhang X, Fok KL, Wong HY, Zhang J, Qiu X, Miao S, Chan HC, Wang L.
    J Cell Sci; 2007 May 01; 120(Pt 9):1521-8. PubMed ID: 17452623
    [Abstract] [Full Text] [Related]

  • 35. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
    Shimamura R, Fraizer GC, Trapman J, Lau YfC, Saunders GF.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 2):2571-80. PubMed ID: 9815658
    [Abstract] [Full Text] [Related]

  • 36. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.
    Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB.
    J Cell Physiol; 1989 Nov 01; 141(2):353-61. PubMed ID: 2808542
    [Abstract] [Full Text] [Related]

  • 37. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
    Wang J, Dicken C, Lustbader JW, Tortoriello DV.
    Fertil Steril; 2009 Apr 01; 91(4):1195-203. PubMed ID: 18328480
    [Abstract] [Full Text] [Related]

  • 38. Involution of the female Mullerian duct of the fetal rat in the organ-culture assay for the detection of Mullerian Inhibiting Substance.
    Price JM, Donahoe PK, Ito Y.
    Am J Anat; 1979 Oct 01; 156(2):265-84. PubMed ID: 506954
    [Abstract] [Full Text] [Related]

  • 39. Gonadoblastoma: immunohistochemical localization of Müllerian-inhibiting substance, inhibin, WT-1, and p53.
    Hussong J, Crussi FG, Chou PM.
    Mod Pathol; 1997 Nov 01; 10(11):1101-5. PubMed ID: 9388060
    [Abstract] [Full Text] [Related]

  • 40. Sex-specific fetal lung development and müllerian inhibiting substance.
    Catlin EA, Powell SM, Manganaro TF, Hudson PL, Ragin RC, Epstein J, Donahoe PK.
    Am Rev Respir Dis; 1990 Feb 01; 141(2):466-70. PubMed ID: 2301861
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.